OncoIndustry
Redefining What’s Possible in MRD

Redefining What’s Possible in MRD

When only trace amounts of ctDNA are present, the MRD test you choose matters

NeXT Personal® is an ultrasensitive, tumor-informed MRD assay designed to detect disease even when ctDNA levels are very low. Because a negative result is only as informative as a test’s ability to detect the disease that’s there.

And low-level disease can still carry clinical significance.

In the landmark TRACERx study, 18% of post-surgical landmark ctDNA detections occurred below 10 parts per million (PPM). Patients with ctDNA detected at these levels had a 3-fold increased risk of recurrence compared with patients with undetectable ctDNA.¹

Cancer biology evolves.

Real-Time Variant Tracker™ is an optional supplemental result in the NeXT Personal MRD test report that tracks selected resistance and therapeutically targetable variants. This includes variants associated with NCCN guidelines-recommended and FDA-approved therapies.

Discover how comprehensive MRD monitoring with NeXT Personal can enhance your clinical practice.

Learn More About NeXT Personal

References.

  1. Black, JRM,. Wan JCM, et al. (2026, May 30). Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non-small cell lung cancer. ASCO Annual Meeting, Chicago, IL, United States
Adjuvant Therapy ASCO 2026 Cancer diagnostics cancer genomics cancer recurrence Circulating tumor DNA clinical oncology ctDNA early cancer detection liquid biopsy Lung cancer Lung Cancer Surveillance Minimal Residual Disease molecular biomarkers molecular diagnostics Molecular Monitoring MRD NeXT Personal non small cell lung cancer NSCLC oncology research Personalis personalized cancer care Postoperative Monitoring Precision Oncology Real-Time Variant Tracker recurrence risk TRACERx study Tumor-Informed MRD Testing Ultrasensitive MRD Detection